在引入减少共同支付计划后,减少了用于牛皮的生物制剂的经济差异
Hyemin Jung1,2, Seong Rae Kim3, Soo Ick Cho4
1Department of Health Policy and Management, Seoul National University College of Medicine, Seoul, South Korea.
Scientific reports
|February 19, 2024
概括
减少共同支付计划 (RCP) 在所有收入水平的中度至重度牛皮患者中增加了生物使用. 这项计划特别有利于低收入人群,可能减少获取差距.
科学领域:
- 皮肤病学 皮肤病学
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 生物疗法为中度至重度的牛皮提供了有效的治疗方法,但与高成本有关.
- 患者获得昂贵的生物治疗可能受到社会经济因素的影响,包括收入水平.
- 了解财政援助计划对治疗利用的影响对于公平的医疗保健至关重要.
研究的目的:
- 调查减少共同支付计划 (RCP) 与生物使用模式的变化之间的关联.
- 分析收入水平如何改变RCP对牛皮患者生物利用的影响.
- 评估RCP在缓解牛皮生物药物获取差异方面的作用.
主要方法:
- 全国范围内对中度至重度牛皮患者的队列研究 (2014-2020).
- 基于收入的物流回归模型来估计生物使用的赔率比率.
- 对生物使用趋势和药物存活率在2017年RCP实施之前和之后的分析.
主要成果:
- 在符合条件的患者中,生物使用在RCP引入后显著增加 (2016年为5.0%,2020年为19.2%).
- 生物利用的增加在低收入和中低收入群体中比较明显,而不是在高收入群体中.
- 在RCP实施后,药物存活率在收入水平之间变得可比,这表明遵守程度有所改善.
结论:
- RCP与所有收入层中中度至重度牛皮患者的生物使用增加有关.
- 该计划对低收入人群的生物接入产生了更显著的积极影响.
- 该RCP显示了减少社会经济差距在获得基本牛皮生物治疗的潜力.
相关概念视频
01:16Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
01:12Analysis of Population Pharmacokinetic Data
256
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
256
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
137
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
137
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
01:28Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
01:24Factors Influencing Drug Absorption: Presystemic Elimination
219
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
219